A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Phase 2 – studying effectiveness and dosage
Conditions:
Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Who can participate
Inclusion Criteria:
* Have type 2 diabetes
* Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
* Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
* Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion Criteria:
* Have type 1 diabetes
БГ